Diastolic Heart Failure disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: DST006 MIFTS: 43	Diastolic Heart Failure Categories: Cardiovascular diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Diastolic Heart Failure

MalaCards integrated aliases for Diastolic Heart Failure:

Name: Diastolic Heart Failure ¹¹ ¹⁴ ¹⁶

Heart Failure, Diastolic ⁴³ ⁷¹

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:9775

ICD9CM ³⁴ 428.3

MeSH ⁴³ D054144

SNOMED-CT ⁶⁸ 418304008

EFO ¹⁶ EFO_1000899

UMLS ⁷¹ C1135196

Sources

Summaries for Diastolic Heart Failure

MalaCards based summary: Diastolic Heart Failure, also known as heart failure, diastolic, is related to hypertension, diastolic and amyloidosis. An important gene associated with Diastolic Heart Failure is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Cardiac conduction and Platelet homeostasis. The drugs Sodium citrate and Sildenafil have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and bone marrow, and related phenotypes are homeostasis/metabolism and muscle

Sources

Related Diseases for Diastolic Heart Failure

Diseases related to Diastolic Heart Failure via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 399)

#	Related Disease	Score	Top Affiliating Genes
1	hypertension, diastolic	30.7	REN ACE
2	amyloidosis	30.5	TTR NPPB INS CRP
3	subclavian steal syndrome	30.4	CRP ACE
4	pericarditis	30.4	TNNT2 TNNI3 NPPB CRP ACE
5	infective endocarditis	30.3	NPPB CRP ACE
6	wild-type amyloidosis	30.3	TTR NPPB
7	central sleep apnea	30.2	REN NPPB CRP ACE
8	atrial fibrillation	30.2	TNNI3 NR3C2 NPPB CRP AGTR1 ACE
9	deficiency anemia	30.2	TTR REN INS CRP ACE
10	cardiomyopathy, familial hypertrophic, 1	30.2	TTN TNNT2 TNNI3 RBM20 MYH6 MYBPC3
11	coronary heart disease 1	30.2	INS CRP ACE
12	raynaud disease	30.1	PDE5A EDN1 CRP AGTR1
13	cardiac tamponade	30.1	TNNI3 REN NPPB CRP ACE
14	aortic valve insufficiency	30.1	TNNI3 REN NPPB CRP ACE
15	alcohol use disorder	30.1	INS CRP ACE
16	polycystic kidney disease 1 with or without polycystic liver disease	30.1	REN NOS3 ACE
17	atrial standstill 1	30.1	TTR NPPB MYBPC3 EDN1
18	diabetes mellitus, ketosis-prone	30.1	REN INS CRP ACE
19	eclampsia	30.0	REN NOS3 EDN1 ACE
20	acute myocarditis	30.0	TNNT2 TNNI3 REN NPPB CRP ACE
21	transient cerebral ischemia	29.9	REN NPPB INS CRP ACE
22	pulmonary hypertension	29.9	REN PRKG1 PDE5A NPPB NOS3 EDN1
23	pulmonary edema	29.9	TNNT2 TNNI3 REN NPPB NOS3 EDN1
24	amyloidosis, hereditary, transthyretin-related	29.9	TTR TNNT2 NPPB MYBPC3
25	cardiac arrest	29.9	TNNT2 TNNI3 NPPB CRP ACE
26	autosomal dominant polycystic kidney disease	29.8	REN NOS3 EDN1 CRP ACE
27	arteriosclerosis	29.8	TTR INS EDN1 CRP ACE
28	respiratory failure	29.7	TTR TTN TNNI3 REN NPPB INS
29	third-degree atrioventricular block	29.7	TTN TNNI3 REN NPPB MYH6 CRP
30	constrictive pericarditis	29.7	TTR TTN TNNT2 TNNI3 REN NPPB
31	peripartum cardiomyopathy	29.7	TTN RBM20 NR3C2 NPPB MYH6 MYBPC3
32	sleep apnea	29.6	REN NPPB NOS3 INS EDN1 CRP
33	angina pectoris	29.6	TNNI3 NPPB NOS3 INS EDN1 CRP
34	peripheral vascular disease	29.6	REN PDE5A NOS3 INS EDN1 CRP
35	myocarditis	29.6	TTN TNNT2 TNNI3 NPPB MYH6 EDN1
36	mitral valve insufficiency	29.6	TTN TNNT2 TNNI3 REN NR3C2 NPPB
37	vascular disease	29.5	TTR PDE5A NOS3 INS EDN1 CRP
38	congestive heart failure	29.5	TTN TNNT2 TNNI3 REN PDE5A NR3C2
39	intermediate coronary syndrome	29.5	TNNT2 TNNI3 REN NPPB INS EDN1
40	apnea, obstructive sleep	29.5	REN NR3C2 NPPB NOS3 INS EDN1
41	atherosclerosis susceptibility	29.5	NOS3 INS EDN1 CRP AGTR1 ACE
42	arteries, anomalies of	29.4	TNNI3 REN NOS3 INS EDN1 CRP
43	kidney disease	29.4	TTR REN NR3C2 NPPB NOS3 INS
44	systolic heart failure	29.4	TTN TNNT2 TNNI3 REN PDE5A NR3C2
45	tricuspid valve insufficiency	29.3	TNNT2 TNNI3 REN PDE5A NR3C2 NPPB
46	aortic valve disease 2	29.2	TTR TTN TNNT2 TNNI3 REN NPPB
47	left bundle branch hemiblock	29.2	TTN TNNT2 TNNI3 REN NR3C2 NPPB
48	stroke, ischemic	29.2	REN NR3C2 NPPB NOS3 INS CRP
49	renal hypertension	29.2	REN NR3C2 NOS3 INS EDN1 CRP
50	pre-eclampsia	29.2	REN PDE5A NOS3 INS EDN1 CRP

Graphical network of the top 20 diseases related to Diastolic Heart Failure:

Sources

Symptoms & Phenotypes for Diastolic Heart Failure

MGI Mouse Phenotypes related to Diastolic Heart Failure:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.3	ACE AGTR1 ATP2A2 CRP EDN1 INS
2	muscle	MP:0005369	10.25	ATP2A2 EDN1 INS MYBPC3 MYH6 NOS3
3	cardiovascular system	MP:0005385	10.23	ACE AGTR1 ATP2A2 CRP EDN1 INS
4	growth/size/body region	MP:0005378	10.22	ACE AGTR1 ATP2A2 EDN1 INS LGALS3
5	renal/urinary system	MP:0005367	10.17	ACE AGTR1 ATP2A2 EDN1 INS LGALS3
6	behavior/neurological	MP:0005386	9.97	ACE AGTR1 ATP2A2 INS LGALS3 MYBPC3
7	immune system	MP:0005387	9.73	ACE AGTR1 ATP2A2 CRP INS LGALS3
8	mortality/aging	MP:0010768	9.5	ACE AGTR1 ATP2A2 EDN1 INS LGALS3

Sources

Drugs & Therapeutics for Diastolic Heart Failure

Drugs for Diastolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

Sildenafil

Approved, Investigational

Phase 4

139755-83-2, 171599-83-0

5212 135398744

Spironolactone

Approved

Phase 4

1952-01-7, 52-01-7

5833

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Angiotensin II

Approved, Investigational

Phase 4

68521-88-0, 11128-99-7, 4474-91-3

172198

Regadenoson

Approved, Investigational

Phase 4

313348-27-5

22451303 219024

Adenosine

Approved, Investigational

Phase 4

58-61-7

60961

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Furosemide

Approved, Vet_approved

Phase 4

54-31-9

3440

Ertugliflozin

Approved, Investigational

Phase 4

1210344-57-2

75075340 44814423

Metoprolol

Approved, Investigational

Phase 4

37350-58-6, 51384-51-1

4171

Carvedilol

Approved, Investigational

Phase 4

72956-09-3

2585

Atenolol

Approved

Phase 4

29122-68-7

2249

Labetalol

Approved

Phase 4

36894-69-6

3869

Acebutolol

Approved, Investigational

Phase 4

37517-30-9

1978

Betaxolol

Approved, Investigational

Phase 4

659-18-7, 63659-18-7

2369

Penbutolol

Approved, Investigational

Phase 4

36507-48-9, 38363-40-5

37464

Sotalol

Approved

Phase 4

959-24-0, 3930-20-9

5253

Bisoprolol

Approved

Phase 4

66722-44-9

2405

Nadolol

Approved

Phase 4

42200-33-9

39147

Propranolol

Approved, Investigational

Phase 4

318-98-9, 525-66-6

62882 4946

Pindolol

Approved, Investigational

Phase 4

13523-86-9

4828

Nebivolol

Approved, Investigational

Phase 4

152520-56-4, 99200-09-6, 118457-14-0

71301

Eplerenone

Approved

Phase 4

107724-20-9

443872

Exenatide

Approved, Investigational

Phase 4

141758-74-9

45588096

Glucagon

Approved

Phase 4

16941-32-5

16133228 16186314

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Phosphodiesterase Inhibitors

Phase 4

Phosphodiesterase 5 Inhibitors

Phase 4

Citrate

Phase 4

Cardiotonic Agents

Phase 4

Angiotensinogen

Phase 4

16133225

Angiotensin Receptor Antagonists

Phase 4

Angiotensin II Type 1 Receptor Blockers

Phase 4

Giapreza

Phase 4

Dopamine Agents

Phase 4

Sodium Potassium Chloride Symporter Inhibitors

Phase 4

Antioxidants

Phase 4

Protective Agents

Phase 4

Calcium, Dietary

Phase 4

calcium channel blockers

Phase 4

Sodium-Glucose Transporter 2 Inhibitors

Phase 4

Sympathomimetics

Phase 4

Adrenergic alpha-Antagonists

Phase 4

Adrenergic alpha-1 Receptor Antagonists

Phase 4

Adrenergic beta-1 Receptor Antagonists

Phase 4

Adrenergic Antagonists

Phase 4

Anti-Arrhythmia Agents

Phase 4

Sympatholytics

Phase 4

Neurotransmitter Agents

Phase 4

Interventional clinical trials:

(show top 50) (show all 142)

#	Name	Status	NCT ID	Phase	Drugs
1	Aldosterone Antagonism in Diastolic Heart Failure	Completed	NCT00108251	Phase 4	Eplerenone;Placebo
2	A Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Determine the Effects of Valsartan on Exercise Time in Subjects With Symptomatic Diastolic Heart Failure	Completed	NCT00171106	Phase 4	valsartan
3	Novel Treatment for Diastolic Heart Failure in Women	Completed	NCT00206232	Phase 4	Spironolactone
4	Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart	Completed	NCT01944384	Phase 4	aldactone
5	Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF	Completed	NCT02589977	Phase 4	regadenoson
6	Randomized Evaluation of Heart Failure With Preserved Ejection Fraction (HFpEF) Patients With Acute Heart Failure and Dopamine (ROPA-DOP) Trial	Completed	NCT01901809	Phase 4	Furosemide;Dopamine
7	A Phase 4, Single-center, Randomized, Parallel Group Study to Assess Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus	Completed	NCT03753087	Phase 4	Empagliflozin
8	SIDAMI - Sildenafil and Diastolic Dysfunction After AMI	Completed	NCT01046838	Phase 4	Sildenafil;Placebo
9	A Phase 4, Randomized, Open Label, Multicenter Prospective Comparative Study To Evaluate The Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure	Recruiting	NCT04160000	Phase 4	Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation;Empiric heart failure drug therapy
10	The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure	Recruiting	NCT04071626	Phase 4	Ertugliflozin 5 mg;Placebo oral tablet
11	N-of-1 Trials for Deprescribing Beta-blockers in HFpEF	Recruiting	NCT04767061	Phase 4	Beta blockers
12	N-of-1 Trials for Deprescribing Beta-blockers in HFpEF	Recruiting	NCT04757584	Phase 4	Beta blockers
13	Echocardiographic Assessment of Pulmonary Transit Time Following Exercise	Active, not recruiting	NCT04336995	Phase 4
14	A Preliminary Study for the Intervention of an N-of-1 Protocol For Medication Optimization	Not yet recruiting	NCT05585125	Phase 4	Beta blocker
15	Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure	Terminated	NCT02053246	Phase 4	Nebivolol
16	The Use of Nesiritide in the Management of Acute Diastolic Heart Failure	Terminated	NCT00083772	Phase 4	Nesiritide
17	Determine the Effectiveness of Eplerenone in Reversing Diastolic Dysfunction, Improving Endothelial Function, and Suppressing Natriuretic Peptides and Collagen Turnover in Patients With Diastolic Heart Failure ( PREDICT Study)	Terminated	NCT00293150	Phase 4	Eplerenone
18	Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction	Terminated	NCT00799435	Phase 4	Exenatide
19	Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction: Phase III, Randomized, Double-blind, Placebo-controlled Trial [ULTIMATE-HFpEF Trial]	Unknown status	NCT01599117	Phase 3	Placebo;Udenafil (Zydena)
20	Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years) (OPTIMIZE-HFPEF)	Unknown status	NCT02425371	Phase 3
21	Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX)	Completed	NCT00763867	Phase 3	Placebo;Sildenafil
22	Exercise Intolerance in Elderly Diastolic Heart Failure	Completed	NCT00123955	Phase 3	Spironolactone;Placebo
23	Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure	Completed	NCT01411735	Phase 3	Enalapril;placebo
24	Pulmonary Hypertension Secondary to Heart Failure With Preserved Systolic Function: a Target of Phosphodiesterase - 5 Inhibition in a 1- Year Duration Study	Completed	NCT01156636	Phase 2, Phase 3	Sildenafil;Placebo
25	Endothelin Receptor Blockade in Heart Failure With Diastolic Dysfunction and Pulmonary Hypertension	Completed	NCT00820352	Phase 3	bosentan;placebo
26	Effects of Sildenafil on Pulmonary Arterial Pressure in Patients With Heart Failure With Preserved Ejection Fraction ( HFpEF) and Pulmonary Hypertension	Completed	NCT01726049	Phase 3	Sildenafil;Placebo
27	Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction	Recruiting	NCT05139472	Phase 3	Empagliflozin 10 MG
28	Sympathetic Renal Denervation in Heart Failure With Normal LV Ejection Fraction: Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction	Terminated	NCT01583881	Phase 2, Phase 3
29	Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction. A 35-week, Single-center, Prospective, Double-blind, Controlled, Randomized, 2x2 Crossover, Interventional Phase II Study, Investigating the Effect of Treatment With Dapagliflozin 10mg od on Left Ventricular Distensibility in Patients With Early HFpEF.	Unknown status	NCT04475042	Phase 2	Dapagliflozin;Placebo
30	A Pilot Study Of ALT-711 In Elderly Patients With Isolated Diastolic Heart Failure: The DIAMOND Study	Completed	NCT00043836	Phase 2	ALT-711
31	A Study of the Acute Hemodynamic and Myocardial Effects of Nesiritide in Diastolic Heart Failure.	Completed	NCT00309868	Phase 1, Phase 2	neseritide
32	A Phase 2 Randomised, Double-Blind, Placebo-Controlled Exploratory Efficacy Study Of Sitaxsentan Sodium To Improve Impaired Exercise Tolerance In Subjects With Diastolic Heart Failure	Completed	NCT00303498	Phase 2	Sitaxsentan sodium;Placebo
33	Randomised Double Blind Placebo Controlled Trial of Perhexiline in Heart Failure With Preserved Ejection Fraction Syndrome (HFpEF)	Completed	NCT00839228	Phase 2	Perhexiline;Placebo
34	Evaluation of Efficacy and Safety of Metoprolol XR in Patients Having Heart Failure With Normal Ejection Fraction: A Randomised, Double Blind,Placebo Controlled Trial	Completed	NCT03882710	Phase 2	Metoprolol XR
35	Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF	Completed	NCT02256345	Phase 2	KNO3;KCl
36	A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients With Heart Failure With Preserved Ejection Fraction	Completed	NCT01163734	Phase 2	Ranolazine
37	Reducing Symptom Burden in Patients With Heart Failure With Preserved Ejection Fraction Using Ubiquinol and/or D-ribose	Completed	NCT03133793	Phase 2	CoQ10;D-Ribose Oral Powder
38	Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function	Completed	NCT01182805	Phase 1, Phase 2
39	A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension	Completed	NCT01431313	Phase 2	Inhaled Nitrite
40	Prevention of Age-associated Cardiac and Vascular Dysfunction Through Nrf2 Signaling Using the Nutritional Supplement Sulforaphane	Recruiting	NCT05408559	Phase 1, Phase 2	Sulforaphane
41	Regress-HFPEF: Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs	Active, not recruiting	NCT02941705	Phase 2
42	A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure	Terminated	NCT00662116	Phase 2	alagebrium;placebo
43	A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure	Terminated	NCT01913301	Phase 2	Alagebrium
44	Acute Hemodynamic Effects of Riociguat (BAY63-2521) in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure: A Randomized, Double-blind, Placebo-controlled, Single-dose Study in Three Ascending Dose Cohorts	Terminated	NCT01172756	Phase 2	Riociguat (BAY63-2521);Placebo
45	If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure	Withdrawn	NCT00757055	Phase 2	Ivabradine;Placebo
46	GRAPe Seed Extract and Ventriculovascular Investigation in Normal Ejection-Fraction Heart Failure	Completed	NCT01185067	Phase 1	grape seed extract (MegaNatural BP, Polyphenolics, Inc.)
47	Phase 1 Open Label, Dose Escalation Trial of Intracoronary Infusion of NAN-101 in Subjects With NYHA Class III Heart Failure	Recruiting	NCT04179643	Phase 1
48	Diastolic Heart Failure Management by Nifedipine	Unknown status	NCT01157481		Conventional therapy plus nifedipine;Conventional therapy
49	Markers of Oxidative Stress Present in Blood in Patients With Diastolic Dysfunction	Unknown status	NCT00846404
50	Effect of Pedometer-Based Walking Intervention on Functional Capacity and Neurohumoral Modulation in Patients With Chronic Heart Failure With Preserved Ejection Fraction: a Multicenter Randomized Controlled Trial	Unknown status	NCT03041376

Search NIH Clinical Center for Diastolic Heart Failure

Cochrane evidence based reviews: heart failure, diastolic

Sources

Genetic Tests for Diastolic Heart Failure

Sources

Anatomical Context for Diastolic Heart Failure

Organs/tissues related to Diastolic Heart Failure:

MalaCards : Heart, Brain, Bone Marrow, Endothelial, Bone, Kidney, Cardiac Myocytes

Sources

Publications for Diastolic Heart Failure

Articles related to Diastolic Heart Failure:

(show top 50) (show all 1308)

#	Title	Authors	PMID	Year
1	Interdisciplinary Protocol for the Management of Vision-Threatening Papilledema. ⁶²	Brady T...Katz BJ	35439211	2022
2	Managing Diastolic Dysfunction Perioperatively. ⁶²	Cios TJ...Roberts SM	36473032	2022
3	High-normal diastolic blood pressure as a risk factor for left ventricular diastolic dysfunction in healthy postmenopausal women. ⁶²	Kimura M...Yamaguchi J	36202980	2022
4	Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here. ⁶²	Tribolet de Abreu T	35604573	2022
5	A Pressing Matter: Compressive Postoperative Hematoma Causing Acute Diastolic Heart Failure. ⁶²	Winters M...Stoupakis G	36369117	2022
6	Peripartum Cardiomyopathy. ⁶²	Shrikhande L...Shrikhande B	36458061	2022
7	Peak O2 -pulse predicts exercise training-induced changes in peak V̇O2 in heart failure with preserved ejection fraction. ⁶²	Mueller S...OptimEx-Clin Study Group	35840541	2022
8	Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST-CHF study. ⁶²	Eidizadeh A...Wachter R	36184749	2022
9	Thirty-day readmission in patients with heart failure with preserved ejection fraction: Insights from the nationwide readmission database. ⁶²	Jha AK...Paul TK	36187428	2022
10	Association between DLCO index and the severity of heart failure: a cross-sectional study. ⁶²	Izadi S...Bakhtiyari M	36082926	2022
11	Imaging in Pulmonary Vascular Disease-Understanding Right Ventricle-Pulmonary Artery Coupling. ⁶²	Tsarova K...Ryan JJ	35950653	2022
12	Obstructive sleep apnea, chronic obstructive pulmonary disease and hypertensive microvascular disease: a cross-sectional observational cohort study. ⁶²	Chew S...Savige J	35922660	2022
13	[Update on diastolic heart failure]. ⁶²	Morbach C...Stork S	35286435	2022
14	Diagnosis of heart failure in the elderly: current status and future perspectives for echocardiographic diagnostic systems. ⁶²	Seo Y	35759116	2022
15	Flood syndrome: a rare case of spontaneous rupture of umbilical hernia in a cirrhotic patient. ⁶²	Gorji L...Brown J	35712608	2022
16	A Rapidly Accumulating Effusion in an Immunocompetent Woman. ⁶²	Kattih Z...Novoselac A	35680319	2022
17	Furosemide-Induced Thrombotic Thrombocytopenic Purpura: A Report of a Rare Case. ⁶²	Chandok T...Khaja M	35812544	2022
18	Trends in Hospital Admissions for Systolic and Diastolic Heart Failure in the United States Between 2004 and 2017. ⁶²	Afzal A...Kale P	35365288	2022
19	Left Atrial Circulatory Assistance in Simulated Diastolic Heart Failure Model: First in Vitro and in Vivo. ⁶²	Miyagi C...Karimov JH	35027316	2022
20	Risk factors, resource use, and cost of postoperative low cardiac output syndrome. ⁶²	Duncan AE...Bokesch P	32800368	2022
21	Machine-learning-based exploration to identify remodeling patterns associated with death or heart-transplant in pediatric-dilated cardiomyopathy. ⁶²	Garcia-Canadilla P...Friedberg MK	35063339	2022
22	The Half-Century Mark: Explant of Ball and Cage Valve after 50 Years. ⁶²	Pupovac SS...Manetta F	35221856	2022
23	Left atrial reservoir strain as a predictor of cardiac outcome in patients with heart failure: the HaFaC cohort study. ⁶²	Bouwmeester S...Houthuizen P	35287575	2022
24	Kaposiform lymphangiomatosis presenting with a Group A Streptococcus pericardial effusion. ⁶²	Koerner T...Indramohan G	35232734	2022
25	The Dysfunctional Scenario of the Major Components Responsible for Myocardial Calcium Balance in Heart Failure Induced by Aortic Stenosis. ⁶²	Silva VLD...Cicogna AC	35262582	2022
26	Surgical management of diastolic heart failure after septal myectomy for obstructive hypertrophic cardiomyopathy. ⁶²	Sun D...Ommen SR	35169725	2022
27	How to build a successful hypertrophic cardiomyopathy team and ensure training the next generation of myectomy surgeons. ⁶²	Schaff HV...Dearani JA	35167375	2022
28	Bariatric surgery decreases the number of future hospital admissions for diastolic heart failure in subjects with severe obesity: a retrospective analysis of the US National Inpatient Sample database. ⁶²	Romero Funes D...Rosenthal RJ	34756668	2022
29	Pulmonary arterial hypertension in the elderly population. ⁶²	Chen CY...Huang WC	34759211	2022
30	Evaluation of left atrial dysfunction by speckle tracking echocardiography in systolic and diastolic heart failure. ⁶²	Ghanaym A...Mahmoud E	35086330	2022
31	Comment on: Bariatric surgery decreases the number of hospital admissions for diastolic heart failure in subjects with severe obesity. Retrospective analysis of the US National Inpatient Sample database. ⁶²	Gagner M	34656453	2022
32	Gastroduodenal ischemia in a patient with severe SARS-CoV-2 infection. ⁶²	Garrido I...Macedo G	34315220	2022
33	Material property alterations for phenotypes of heart failure with preserved ejection fraction: A numerical study of subject-specific porcine models. ⁶²	Weissmann J...Marom G	36312535	2022
34	The Value of Echocardiography Combined with NT-pro BNP Level in Assessment and Prognosis of Diastolic Heart Failure. ⁶²	Chen S...Li P	35169397	2022
35	Diagnostic Tools for Cardiac Amyloidosis: A Pragmatic Comparison of Pathology, Imaging and Laboratories. ⁶²	Joury A...Nativi-Nicolau J	35007639	2022
36	Application of Combined Detection of Echocardiography and Serum NT-ProBNP in the Diagnosis of Diastolic Heart Failure and Its Effect on Left Ventricular Morphology and Diastolic Function. ⁶²	Yang W...Liang D	35656473	2022
37	Pediatric Diastolic Heart Failure: Clinical Features Description of 421 Cases. ⁶²	Pan B...Tian J	35586825	2022
38	Evaluating the adverse outcome of subtypes of heart failure with preserved ejection fraction defined by machine learning: A systematic review focused on defining high risk phenogroups. ⁶²	Rabkin SW	35391918	2022
39	Myofilament Phosphorylation in Stem Cell Treated Diastolic Heart Failure. ⁶²	Soetkamp D...Van Eyk JE	34641704	2021
40	NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial. ⁶²	Dumeny L...Cavallari LH	34569641	2021
41	Pericardiectomy for Constrictive Pericarditis: Analysis of Outcomes. ⁶²	Liu VC...Ramakrishna H	33722460	2021
42	Influence of baseline parameters on one-year physical, mental, and health-related quality of life in patients with heart failure and preserved ejection fraction. ⁶²	Fitz J...Herrmann-Lingen C	34480783	2021
43	Predictors of thirty-day readmission in nonagenarians presenting with acute heart failure with preserved ejection fraction: a nationwide analysis. ⁶²	Maraey A...Alam A	35136396	2021
44	An Unusual Case of Heart Failure: Sometimes When You Hear Hoof Beats You Should Think of Zebras. ⁶²	Butt EJ...Boyars MC	35141062	2021
45	Immunoglobulin Light Chain Amyloidosis Presenting as Inferior Vena Cava Thrombosis. ⁶²	Axentiev A...Setya V	34743583	2021
46	Constrictive pericarditis following heart transplantation: Reality or fiction? ⁶²	Fadel BM...Mohty D	34755387	2021
47	Comparing outcomes of diabetic ketoacidosis hospitalisations in patients with diastolic heart failure: A retrospective propensity matched analysis of the nationwide inpatient sample. ⁶²	Shaka H...Kichloo A	33440066	2021
48	Cardiac Amyloidosis: Presentations, Diagnostic Work-up and Collaborative Approach for Comprehensive Clinical Management. ⁶²	Joury A...Krim SR	34175153	2021
49	Factors predicting futility of liver transplant in elderly recipients: A single-center experience. ⁶²	Kleb C...Modaresi Esfeh J	34722171	2021
50	Deep-Learning Models for the Echocardiographic Assessment of Diastolic Dysfunction. ⁶²	Pandey A...Sengupta PP	34023263	2021

Sources

Genes for Diastolic Heart Failure

Genes related to Diastolic Heart Failure (0 elite genes):

(show all 23)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ACE	Angiotensin I Converting Enzyme	Protein Coding	7.26	DISEASES inferred ¹⁴
2	NPPB	Natriuretic Peptide B	Protein Coding	7.19	DISEASES inferred ¹⁴
3	TTN	Titin	Protein Coding	7.08	DISEASES inferred ¹⁴
4	REN	Renin	Protein Coding	6.94	DISEASES inferred ¹⁴
5	PDE5A	Phosphodiesterase 5A	Protein Coding	6.25	DISEASES inferred ¹⁴
6	NR3C2	Nuclear Receptor Subfamily 3 Group C Member 2	Protein Coding	6.18	DISEASES inferred ¹⁴
7	TNNI3	Troponin I3, Cardiac Type	Protein Coding	6.04	DISEASES inferred ¹⁴
8	EDN1	Endothelin 1	Protein Coding	5.77	DISEASES inferred ¹⁴
9	RBM20	RNA Binding Motif Protein 20	Protein Coding	5.74	DISEASES inferred ¹⁴
10	AGTR1	Angiotensin II Receptor Type 1	Protein Coding	5.67	DISEASES inferred ¹⁴
11	ATP2A2	ATPase Sarcoplasmic/Endoplasmic Reticulum Ca2+ Transporting 2	Protein Coding	5.66	DISEASES inferred ¹⁴
12	CRP	C-Reactive Protein	Protein Coding	5.65	DISEASES inferred ¹⁴
13	PRKG1	Protein Kinase CGMP-Dependent 1	Protein Coding	5.6	DISEASES inferred ¹⁴
14	MYBPC3	Myosin Binding Protein C3	Protein Coding	5.59	DISEASES inferred ¹⁴
15	TTR	Transthyretin	Protein Coding	5.53	DISEASES inferred ¹⁴
16	MYH6	Myosin Heavy Chain 6	Protein Coding	5.52	DISEASES inferred ¹⁴
17	LGALS3	Galectin 3	Protein Coding	5.48	DISEASES inferred ¹⁴
18	INS	Insulin	Protein Coding	5.46	DISEASES inferred ¹⁴
19	TNNT2	Troponin T2, Cardiac Type	Protein Coding	5.46	DISEASES inferred ¹⁴
20	NOS3	Nitric Oxide Synthase 3	Protein Coding	5.45	DISEASES inferred ¹⁴
21	CCN2	Cellular Communication Network Factor 2	Protein Coding	5.44	DISEASES inferred ¹⁴
22	MME	Membrane Metalloendopeptidase	Protein Coding	5.42	DISEASES inferred ¹⁴
23	IL6	Interleukin 6	Protein Coding	5.33	DISEASES inferred ¹⁴

Sources

Variations for Diastolic Heart Failure

Sources

Expression for Diastolic Heart Failure

Search GEO for disease gene expression data for Diastolic Heart Failure.

Sources

Pathways for Diastolic Heart Failure

Pathways related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Cardiac conduction ⁶⁶ Show member pathways Classical Kir channels ⁶⁶ Ion homeostasis ⁶⁶ Ion transport by P-type ATPases ⁶⁶ Muscle contraction ⁶⁶ Phase 1 - inactivation of fast Na+ channels ⁶⁶ Phase 2 - plateau phase ⁶⁶ Phase 3 - rapid repolarisation ⁶⁶ Phase 4 - resting membrane potential ⁶⁶ Physiological factors ⁶⁶ Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK) ⁶⁶ Tandem pore domain halothane-inhibited K+ channel (THIK) ⁶⁶ Tandem pore domain potassium channels ⁶⁶ TWIK related potassium channel (TREK) ⁶⁶ TWIK-related alkaline pH activated K+ channel (TALK) ⁶⁶ TWIK-related spinal cord K+ channel (TRESK) ⁶⁶ TWIK-releated acid-sensitive K+ channel (TASK) ⁶⁶	12.43	TTN TNNT2 TNNI3 PDE5A MYH6 MYBPC3
2	Platelet homeostasis ⁶⁶ Show member pathways Elevation of cytosolic Ca2+ levels ⁶⁶ Platelet calcium homeostasis ⁶⁶ Platelet sensitization by LDL ⁶⁶ Prostacyclin signalling through prostacyclin receptor ⁶⁶ Reduction of cytosolic Ca++ levels ⁶⁶	11.97	PRKG1 PDE5A NOS3 ATP2A2
3	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.61	TNNT2 TNNI3 INS
4	Cardiac progenitor differentiation ⁷⁴	11.28	TNNT2 TNNI3 MYH6 INS
5	Striated muscle contraction pathway ⁷⁴ Show member pathways Striated Muscle Contraction ⁶⁶	11.22	TTN TNNT2 TNNI3 MYH6 MYBPC3
6	ACE Inhibitor Pathway, Pharmacodynamics ⁶⁰ Show member pathways ACE inhibitor pathway ⁷⁴ Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics ⁶⁰ Conversion of angiotensinogen to angiotensin II ⁷⁴ Defective SERPING1 causes hereditary angioedema ⁶⁶ Downregulation of ACE2 by SARS-CoV-2 spike protein ⁷⁴ Kinin-Kallikrein pathway ⁷⁴ Non-classical role of vitamin D ⁷⁴ RAS and bradykinin pathways in COVID-19 ⁷⁴ Renin-angiotensin-aldosterone system (RAAS) ⁷⁴ SARS-CoV-2 and ACE2 receptor: molecular mechanisms ⁷⁴	11.16	REN PRKG1 NR3C2 NOS3 AGTR1 ACE
7	Nitric oxide stimulates guanylate cyclase ⁶⁶ Show member pathways cGMP effects ⁶⁶	11.12	PRKG1 PDE5A NOS3
8	Endothelin pathways ⁷⁴	10.99	NOS3 EDN1 ATP2A2
9	NO-dependent CFTR activation (normal and CF) ²²	10.55	PDE5A NOS3

Sources

GO Terms for Diastolic Heart Failure

Cellular components related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	myofibril	GO:0030016	9.56	TNNT2 TNNI3 MYH6
2	sarcomere	GO:0030017	9.56	TNNT2 TNNI3 MYH6 MYBPC3
3	cardiac Troponin complex	GO:1990584	9.46	TNNT2 TNNI3
4	cardiac myofibril	GO:0097512	9.1	TNNT2 TNNI3 MYBPC3

Biological processes related to Diastolic Heart Failure according to GeneCards Suite gene sharing:

(show all 16)

#	Name	GO ID	Score	Top Affiliating Genes
1	response to lipopolysaccharide	GO:0032496	10.15	REN NOS3 EDN1 ACE
2	muscle contraction	GO:0006936	10.03	TTN TNNT2 TNNI3 MYH6
3	vasodilation	GO:0042311	9.97	INS NOS3 NPPB
4	sarcomere organization	GO:0045214	9.95	MYH6 TNNT2 TTN
5	regulation of vasoconstriction	GO:0019229	9.88	ACE AGTR1 EDN1
6	regulation of cardiac muscle contraction by calcium ion signaling	GO:0010882	9.86	TNNI3 ATP2A2
7	ventricular cardiac muscle tissue morphogenesis	GO:0055010	9.86	TNNT2 TNNI3 MYH6 MYBPC3
8	vasoconstriction	GO:0042310	9.85	EDN1 CRP ACE
9	cardiac muscle contraction	GO:0060048	9.85	MYBPC3 MYH6 TNNI3 TNNT2 TTN
10	body fluid secretion	GO:0007589	9.84	NPPB EDN1
11	regulation of systemic arterial blood pressure by endothelin	GO:0003100	9.83	NOS3 EDN1
12	regulation of systemic arterial blood pressure by renin-angiotensin	GO:0003081	9.81	AGTR1 ACE
13	renin-angiotensin regulation of aldosterone production	GO:0002018	9.76	REN AGTR1
14	striated muscle contraction	GO:0006941	9.72	TTN TNNI3 MYH6
15	regulation of blood pressure	GO:0008217	9.7	REN NPPB NOS3 MYH6 EDN1 ACE
16	blood vessel diameter maintenance	GO:0097746	9.28	NPPB NOS3 EDN1 AGTR1 ACE